叉头转录因子1/3在肝纤维化中的作用

李天; 吴岩; 姬婷; 金振晓

doi:10.3969/j.issn.1001-5256.2019.08.043

叉头转录因子1/3在肝纤维化中的作用

DOI: 10.3969/j.issn.1001-5256.2019.08.043

第四军医大学西京医院心血管外科
第四军医大学基础医学院
西北大学生命科学学院

基金项目:

国家自然科学基金(81570231)；西京医院科学发展基金(YYKJFZJJ2018Y083)；陕西省重点研发计划(2019ZDLSF01-01-02)；

详细信息

中图分类号: R575.2
计量
- 文章访问数: 880
- HTML全文浏览量: 26
- PDF下载量: 215
- 被引次数: 0
出版历程
- 收稿日期: 2019-01-28
- 出版日期: 2019-08-20

Role of FOXO1/3 in the pathogenesis of hepatic fibrosis

Department of Cardiovascular Surgery, Xijing Hospital of Fourth Military Medical University

Research funding:

摘要

摘要: 肝纤维化是指各种致病因子所致肝内结缔组织异常增生的病理过程。肝纤维化伴随于肝损伤修复愈合的全过程,慢性长期的损伤因素会诱导纤维化进展成肝硬化。流行病学数据显示,2017年我国共报告乙型肝炎新发病例118. 05万、丙型肝炎24. 3万。慢性病毒性肝炎带来了沉重的社会经济负担。叉头转录因子(FOXO)从属于叉头状家族,在细胞的各项生命活动中发挥着重要作用。研究发现,FOXO1/3可通过TGFβ通路调节肝星状细胞活力,在肝纤维化病变中扮演着重要角色。综述了肝纤维化病变机制、FOXO1/3对肝纤维化的调控机制,以及FOXO1/3(肝纤维化病变位点之一)的靶向治疗研究进展。
- 肝硬化 /
- 叉头转录因子类
Abstract: Hepatic fibrosis refers to the pathological process of abnormal proliferation of connective tissue in the liver caused by various pathogenic factors. Hepatic fibrosis is observed in the whole process of liver injury repair and healing, and long-term chronic injury factors may induce the progression of hepatic fibrosis into liver cirrhosis. Epidemiological data show that there are 1. 1805 million new cases of hepatitis B and 243 thousand cases of hepatitis C reported in 2017. Chronic viral hepatitis has brought heavy social and economic burden. Forkhead transcription factor (FOXO) belongs to the forkhead family and plays an important role in various cell life activities. Studies have shown that FOXO1/3 can regulate hepatic stellate cell activity through the TGFβ pathway and thus play an important role in hepatic fibrosis. This article reviews the research advances in the pathogenesis of hepatic fibrosis, the mechanism of action of FOXO1/3 in the regulation of hepatic fibrosis, and targeted therapy for FOXO1/3 (one of the sites for hepatic fibrosis) .
- liver cirrhosis /
- forkhead transcription factors

HTML全文

参考文献(52)

[1] BULLOCK M. FOXO factors and breast cancer:Outfoxing endocrine resistance[J]. Endocr Relat Cancer, 2016, 23 (2) :113-130.

[2] WEIGEL D, JURGENS G, KUTTNER F, et al. The homeotic gene fork head encodes a nuclear protein and is expressed in the terminal regions of the Drosophila embryo[J]. Cell, 1989, 57 (4) :645-658.

[3] KUMAZOE M, TAKAI M, BAE J, et al. FOXO3 is essential for CD44 expression in pancreatic cancer cells[J]. Oncogene, 2017, 36 (19) :2643-2654.

[4] WILHELM K, HAPPEL K, EELEN G, et al. FOXO1 couples metabolic activity and growth state in the vascular endothelium[J]. Nature, 2016, 529 (7585) :216-220.

[5] DAS SK, DESAULNIERS J, DYCK JR, et al. Resveratrol mediates therapeutic hepatic effects in acquired and genetic murine models of iron-overload[J]. Liver Int, 2016, 36 (2) :246-257.

[6] de MAGALHAES JP, WUTTKE D, WOOD SH, et al. Genomeenvironment interactions that modulate aging:Powerful targets for drug discovery[J]. Pharmacol Rev, 2012, 64 (1) :88-101.

[7] SALMINEN A, KAARNIRANTA K, KAUPPINEN A. Age-related changes in AMPK activation:Role for AMPK phosphatases and inhibitory phosphorylation by upstream signaling pathways[J]. Ageing Res Rev, 2016, 28:15-26.

[8] NANTHAKUMAR CB, HATLEY RJ, LEMMA S, et al. Dissecting fibrosis:Therapeutic insights from the small-molecule toolbox[J]. Nat Rev Drug Discov, 2015, 14 (10) :693-720.

[9] ROCKEY DC, BELL PD, HILL JA. Fibrosis—a common pathway to organ injury and failure[J]. N Engl J Med, 2015, 372 (12) :1138-1149.

[10] MARTIN K, PRITCHETT J, LLEWELLYN J, et al. PAK proteins and YAP-1 signalling downstream of integrin beta-1 in myofibroblasts promote liver fibrosis[J]. Nat Commun, 2016, 7:12502.

[11] GRESSNER OA, RIZK MS, KOVALENKO E, et al. Changing the pathogenetic roadmap of liver fibrosis? Where did it start;where will it go?[J]. J Gastroenterol Hepatol, 2008, 23 (7 Pt1) :1024-1035.

[12] LI Y, LU LG. Molecular basis of hepatic fibrosis and current status of its diagnosis and treatment[J]. J Clin Hepatol, 2018, 34 (1) :12-15. (in Chinese) 李妍, 陆伦根.肝纤维化的分子基础与临床诊治现状[J].临床肝胆病杂志, 2018, 34 (1) :12-15.

[13] ZHANG W, JIA JD. Pathogenesis and new therapeutic targets of liver fibrosis[J]. J Clin Hepatol, 2017, 33 (3) :409-412. (in Chinese) 张伟, 贾继东.肝纤维化的发病机制及治疗新靶点[J].临床肝胆病杂志, 2017, 33 (3) :409-412.

[14] SAITO I, SARUTA T. Therapeutic drug monitoring of inhibitors of renin-angiotensin system[J]. Nihon Rinsho, 1990, 48 (Suppl) :1146-1148.

[15] BENTEN D, KUMARAN V, JOSEPH B, et al. Hepatocyte transplantation activates hepatic stellate cells with beneficial modulation of cell engraftment in the rat[J]. Hepatology, 2005, 42 (5) :1072-1081.

[16] XU MY, HU JJ, SHEN J, et al. Stat3 signaling activation crosslinking of TGF-beta1 in hepatic stellate cell exacerbates liver injury and fibrosis[J]. Biochim Biophys Acta, 2014, 1842 (11) :2237-2245.

[17] CAI W, ZHAO L, LI HR, et al. Influence of kaempferol on TGF-beta1/Smads signal path in liver tissue of mice with Schistosoma japonicum infection[J]. Chin J Schi Contl, 2014, 26 (4) :399-404, 419. (in Chinese) 蔡文, 赵雷, 李华蓉, 等.山奈酚对感染日本血吸虫小鼠TGF-β1/Smads信号通路的影响[J].中国血吸虫病防治杂志, 2014, 26 (4) :399-404, 419.

[18] CUTRONEO KR. TGF-beta-induced fibrosis and SMAD signaling:Oligo decoys as natural therapeutics for inhibition of tissue fibrosis and scarring[J]. Wound Repair Regen, 2007, 15 (Suppl 1) :s54-s60.

[19] HEMMANN S, GRAF J, RODERFELD M, et al. Expression of MMPs and TIMPs in liver fibrosis-a systematic review with special emphasis on anti-fibrotic strategies[J]. J Hepatol, 2007, 46 (5) :955-975.

[20] BREW K, NAGASE H. The tissue inhibitors of metalloproteinases (TIMPs) :An ancient family with structural and functional diversity[J]. Biochim Biophys Acta, 2010, 1803 (1) :55-71.

[21] RAMIREZ T, LI YM, YIN S, et al. Aging aggravates alcoholic liver injury and fibrosis in mice by downregulating sirtuin 1 expression[J]. J Hepatol, 2017, 66 (3) :601-609.

[22] WU X, WU X, MA Y, et al. CUG-binding protein 1 regulates HSC activation and liver fibrogenesis[J]. Nat Commun, 2016, 7:13498.

[23] LAINE F, RUIVARD M, LOUSTAUD-RATTI V, et al. Metabolic and hepatic effects of bloodletting in dysmetabolic iron overload syndrome:A randomized controlled study in 274 patients[J]. Hepatology, 2017, 65 (2) :465-474.

[24] DAS SK, DESAULNIERS J, DYCK JR, et al. Resveratrol mediates therapeutic hepatic effects in acquired and genetic murine models of iron-overload[J]. Liver Int, 2016, 36 (2) :246-257.

[25] HUANG CK, YU T, de la MONTE SM, et al. Restoration of Wnt/beta-catenin signaling attenuates alcoholic liver disease progression in a rat model[J]. J Hepatol, 2015, 63 (1) :191-198.

[26] PASSINO MA, ADAMS RA, SIKORSKI SL, et al. Regulation of hepatic stellate cell differentiation by the neurotrophin receptor p75NTR[J]. Science, 2007, 315 (5820) :1853-1856.

[27] LOPEZ-SANCHEZ I, DUNKEL Y, ROH YS, et al. GIV/Girdin is a central hub for profibrogenic signalling networks during liver fibrosis[J]. Nat Commun, 2014, 5:4451.

[28] ADACHI M, OSAWA Y, UCHINAMI H, et al. The forkhead transcription factor FoxO1 regulates proliferation and transdifferentiation of hepatic stellate cells[J]. Gastroenterology, 2007, 132 (4) :1434-1446.

[29] LI A, WANG J, WU M, et al. The inhibition of activated hepatic stellate cells proliferation by arctigenin through G0/G1phase cell cycle arrest:Persistent p27 (Kip1) induction by interfering with PI3K/Akt/FOXO3a signaling pathway[J]. Eur J Pharmacol, 2015, 747:71-87.

[30] MICHEAU O. Cellular FLICE-inhibitory protein:An attractive therapeutic target?[J]. Expert Opin Ther Targets, 2003, 7 (4) :559-573.

[31] PARK SJ, SOHN HY, YOON J, et al. Down-regulation of FoxO-dependent c-FLIP expression mediates TRAIL-induced apoptosis in activated hepatic stellate cells[J]. Cell Signal, 2009, 21 (10) :1495-1503.

[32] DURAN A, HERNANDEZ ED, REINA-CAMPOS M, et al.p62/SQSTM1 by binding to vitamin D receptor inhibits hepatic stellate cell activity, fibrosis, and liver cancer[J]. Cancer Cell, 2016, 30 (4) :595-609.

[33] GOURDIE RG, DIMMELER S, KOHL P. Novel therapeutic strategies targeting fibroblasts and fibrosis in heart disease[J]. Nat Rev Drug Discov, 2016, 15 (9) :620-638.

[34] ADACHI M, OSAWA Y, UCHINAMI H, et al. The forkhead transcription factor FoxO1 regulates proliferation and transdifferentiation of hepatic stellate cells[J]. Gastroenterology, 2007, 132 (4) :1434-1446.

[35] GAGGAR A, WEATHINGTON N. Bioactive extracellular matrix fragments in lung health and disease[J]. J Clin Invest, 2016, 126 (9) :3176-3184.

[36] CROSAS-MOLIST E, FABREGAT I. Role of NADPH oxidases in the redox biology of liver fibrosis[J]. Redox Biol, 2015, 6:106-111.

[37] OZAKI I, HAMAJIMA H, MATSUHASHI S, et al. Regulation of TGF-beta1-induced pro-apoptotic signaling by growth factor receptors and extracellular matrix receptor integrins in the liver[J]. Front Physiol, 2011, 2:78.

[38] DENG G, HUANG FZ, LIU XY, et al. Construction of recom binant adenovirus containing Akt and its expression in the liver of cirrhotic rats[J]. Chin J Gen Surg, 2008, 17 (7) :687-691. (in Chinese) 邓刚, 黄飞舟, 刘浔阳, 等.重组Akt腺病毒的构建及其在肝硬化大鼠肝脏中的表达[J].中国普通外科杂志, 2008, 17 (7) :687-691.

[39] VALDERRAMA-CARVAJAL H, COCOLAKIS E, LACERTE A, et al. Activin/TGF-beta induce apoptosis through Smad-dependent expression of the lipid phosphatase SHIP[J]. Nat Cell Biol, 2002, 4 (12) :963-969.

[40] KIM BC. FoxO3a mediates transforming growth factor-beta1-induced apoptosis in Fa O rat hepatoma cells[J]. BMB Rep, 2008, 41 (10) :728-732.

[41] PIAO SG, KANG SH, LIM SW, et al. Influence of N-acetylcysteine on Klotho expression and its signaling pathway in experimental model of chronic cyclosporine nephropathy in mice[J]. Transplantation, 2013, 96 (2) :146-153.

[42] BOSE SK, KIM H, MEYER K, et al. Forkhead box transcription factor regulation and lipid accumulation by hepatitis C virus[J]. J Virol, 2014, 88 (8) :4195-4203.

[43] van den BORNE SW, DIEZ J, BLANKESTEIJN WM, et al. Myocardial remodeling after infarction:The role of myofibroblasts[J]. Nat Rev Cardiol, 2010, 7 (1) :30-37.

[44] PRABHU SD, FRANGOGIANNIS NG. The biological basis for cardiac repair after myocardial infarction:From inflammation to fibrosis[J]. Circ Res, 2016, 119 (1) :91-112.

[45] MAZZOCCOLI G, de COSMO S, MAZZA T. The biological clock:A pivotal hub in non-alcoholic fatty liver disease pathogenesis[J]. Front Physiol, 2018, 9:193.

[46] SHIRASAKI T, HONDA M, SHIMAKAMI T, et al. Impaired interferon signaling in chronic hepatitis C patients with advanced fibrosis via the transforming growth factor beta signaling pathway[J]. Hepatology, 2014, 60 (5) :1519-1530.

[47] HARIHARAN N, MAEJIMA Y, NAKAE J, et al. Deacetylation of Fox O by Sirt1 plays an essential role in mediating starvation-induced autophagy in cardiac myocytes[J]. Circ Res, 2010, 107 (12) :1470-1482.

[48] SENGUPTA A, MOLKENTIN JD, PAIK JH, et al. Fox O transcription factors promote cardiomyocyte survival upon induction of oxidative stress[J]. J Biol Chem, 2011, 286 (9) :7468-7478.

[49] ZHANG K, LI L, QI Y, et al. Hepatic suppression of Foxo1and Foxo3 causes hypoglycemia and hyperlipidemia in mice[J]. Endocrinology, 2012, 153 (2) :631-646.

[50] NAKAE J, CAO Y, OKI M, et al. Forkhead transcription factor FoxO1 in adipose tissue regulates energy storage and expenditure[J]. Diabetes, 2008, 57 (3) :563-576.

[51] KAMEI Y, MIURA S, SUZUKI M, et al. Skeletal muscle FOXO1 (FKHR) transgenic mice have less skeletal muscle mass, down-regulated Type I (slow twitch/red muscle) fiber genes, and impaired glycemic control[J]. J Biol Chem, 2004, 279 (39) :41114-41123.

[52] MILAN G, ROMANELLO V, PESCATORE F, et al. Regulation of autophagy and the ubiquitin-proteasome system by the FoxO transcriptional network during muscle atrophy[J]. Nat Commun, 2015, 6:6670.

施引文献

资源附件(0)

访问统计